203 related articles for article (PubMed ID: 26195179)
1. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.
Park KT; Colletti RB; Rubin DT; Sharma BK; Thompson A; Krueger A
Am J Gastroenterol; 2016 Jan; 111(1):15-23. PubMed ID: 26195179
[TBL] [Abstract][Full Text] [Related]
2. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
3. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
6. The cost of hospitalization in Crohn's disease.
Cohen RD; Larson LR; Roth JM; Becker RV; Mummert LL
Am J Gastroenterol; 2000 Feb; 95(2):524-30. PubMed ID: 10685762
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013.
Bounthavong M; Li M; Watanabe JH
Res Social Adm Pharm; 2017; 13(3):530-538. PubMed ID: 27263802
[TBL] [Abstract][Full Text] [Related]
9. Diagnoses, procedures, drug utilization, comorbidities, and cost of health care for people with epilepsy in 2012.
Wilner AN; Sharma BK; Thompson A; Soucy A; Krueger A
Epilepsy Behav; 2014 Dec; 41():83-90. PubMed ID: 25461195
[TBL] [Abstract][Full Text] [Related]
10. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
Carter CT; Waters HC; Smith DB
Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
[TBL] [Abstract][Full Text] [Related]
11. Mental Health Costs of Inflammatory Bowel Diseases.
Szigethy E; Murphy SM; Ehrlich OG; Engel-Nitz NM; Heller CA; Henrichsen K; Lawton R; Meadows P; Allen JI
Inflamm Bowel Dis; 2021 Jan; 27(1):40-48. PubMed ID: 32095835
[TBL] [Abstract][Full Text] [Related]
12. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
Patil SA; Flasar MH; Lin J; Lingohr-Smith M; Skup M; Wang S; Chao J; Cross RK
Dig Dis Sci; 2019 Jan; 64(1):60-67. PubMed ID: 30311154
[TBL] [Abstract][Full Text] [Related]
13. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
Wu EQ; Mulani PM; Yu AP; Tang J; Pollack PF
Value Health; 2008; 11(5):820-9. PubMed ID: 18489509
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
16. Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.
Boschetti G; Nancey S; Daniel F; Pariente B; Lerebours E; Duclos B; Bourreille A; Cadiot G; Fumery M; Moreau J; Marteau P; Bouhnik Y; Louis E; Flourié B;
Inflamm Bowel Dis; 2016 Dec; 22(12):2924-2932. PubMed ID: 27846194
[TBL] [Abstract][Full Text] [Related]
17. Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis.
Lichtenstein GR; Shahabi A; Seabury SA; Lakdawalla DN; Espinosa OD; Green S; Brauer M; Baldassano RN
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):889-897.e10. PubMed ID: 31326606
[TBL] [Abstract][Full Text] [Related]
18. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
19. Trends and Attributable Costs of Anorectal Involvement in Pediatric Crohn's Disease.
DeLong CG; Kulaylat AN; Kulaylat AS; Hollenbeak CS; Cilley RE; Rocourt DV
J Surg Res; 2018 Dec; 232():113-120. PubMed ID: 30463706
[TBL] [Abstract][Full Text] [Related]
20. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
